Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 16/20 | 0.67 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.67 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.67 |
| ▸ | DRD2 | P14416 | 2/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.67 |
| ▸ | PGR | P06401 | 1/20 | 0.67 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | DRD3 | P35462 | 1/20 | 0.67 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salmefamol SCHEMBL30361710 | 1.00 | ADRB2 (0.67) | ADRB2ADRB1ADRB3DRD2SLC6A4 | |
| Salmefamol SCHEMBL20285629 | 1.00 | ADRB2 (0.67) | ADRB2ADRB1ADRB3DRD2SLC6A4 | |
| SCHEMBL11180299 | 0.90 | ADRB2 (0.69) | ADRB2ADRB1ADRB3DRD2SLC6A4 | |
| SCHEMBL4255159 | 0.89 | ADRB2 (0.71) | ADRB2ADRB1ADRB3DRD2SLC6A4 | |
| Arformoterol SCHEMBL5849657 | 0.89 | ADRB2 (0.87) | ADRB2ADRB1ADRB3DRD2SLC6A4 | |
| SCHEMBL4255154 | 0.89 | ADRB2 (0.71) | ADRB2ADRB1ADRB3DRD2SLC6A4 | |
| SCHEMBL11174404 | 0.89 | ADRB2 (0.61) | ADRB2ADRB1ADRB3SLC6A4ADRA1A | |
| Salmefamol SCHEMBL2221384 | 0.89 | ADRB2 (0.68) | ADRB2ADRB1ADRB3DRD2SLC6A4 | |
| SCHEMBL11180151 | 0.89 | ADRB2 (0.56) | ADRB2ADRB1ADRB3DRD2SLC6A4 | |
| SCHEMBL11810215 | 0.88 | ADRB2 (0.73) | ADRB2ADRB1ADRB3DRD2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3922 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250134835-A1 | COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) | CURASEN THERAPEUTICS, INC. | 2025-05-01 | — | — | US | claimed |
| US-20240398729-A1 | Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders | DUKE UNIVERSITY (US) | 2024-12-05 | — | — | US | claimed |
| EP-4126138-B1 | AEROSOL DELIVERY OF AT LEAST TWO LIQUID COMPOSITIONS | INVOX BELGIUM NV (BE) | 2024-10-16 | — | — | EP | claimed |
| WO-2023250334-A1 | COMPOSITIONS AND METHODS INVOLVING ISOLATED COMPOUNDS | CURASEN THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | claimed |
| WO-2023250332-A1 | COMPOSITIONS AND METHODS INVOLVING ISOLATED COMPOUNDS | CURASEN THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | claimed |
| US-20230414588-A1 | COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) | CURASEN THERAPEUTICS, INC. | 2023-12-28 | — | — | US | claimed |
| WO-2023225021-A1 | COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) | CURASEN THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | claimed |
| EP-4126138-A1 | AEROSOL DELIVERY OF AT LEAST TWO LIQUID COMPOSITIONS | Softhale NV (BE) | 2023-02-08 | — | — | EP | claimed |
| WO-2022123511-A1 | A COMPOSITION COMPRISING FEXOFENADINE | CELLIX BIO PRIVATE LIMITED (IN) | 2022-06-16 | — | — | WO | claimed |
| US-20220184052-A1 | COMPOSITION COMPRISING FEXOFENADINE | CELLIX BIO PRIVATE LIMITED (IN) | 2022-06-16 | — | — | US | claimed |
| CN-1170356-A | Aerosol drug formulations | ASTRA AB (SE) | 1998-01-14 | — | — | CN | claimed |
| US-5656286-A | BLEND OF TWO POLYMERS; PRESSURE SENSITIVE ADHESIVE | NOVEN PHARMACEUTICALS, INC. (US) | 1997-08-12 | — | — | US | claimed |
| CN-1143318-A | Transdermal device containing polyvinylpyrrolidone as dissolution enhancer | NOVEN PHARMA (US) | 1997-02-19 | — | — | CN | claimed |
| EP-0737066-A1 | TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER | NOVEN PHARMACEUTICALS, INC. (US) | 1996-10-16 | — | — | EP | claimed |
| WO-1995018603-A1 | TRANSDERMAL DEVICE CONTAINING POLYVINYLPYRROLIDONE AS SOLUBILITY ENHANCER | NOVEN PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | claimed |
| EP-0591432-A4 | SOLUBILITY PARAMETER BASED DRUG DELIVERY SYSTEM AND METHOD FOR ALTERING DRUG SATURATION CONCENTRATION. | NOVEN PHARMA (US) | 1995-05-17 | — | — | EP | claimed |
| CN-1088778-A | Based on the drug delivery system of solubility parameters and the method for change medicine saturated concentration | NOVEN PHARMA (US) | 1994-07-06 | — | — | CN | claimed |
| EP-0591432-A1 | SOLUBILITY PARAMETER BASED DRUG DELIVERY SYSTEM AND METHOD FOR ALTERING DRUG SATURATION CONCENTRATION | NOVEN PHARMACEUTICALS, INC. (US) | 1994-04-13 | — | — | EP | claimed |
| WO-1993000058-A1 | SOLUBILITY PARAMETER BASED DRUG DELIVERY SYSTEM AND METHOD FOR ALTERING DRUG SATURATION CONCENTRATION | NOVEN PHARMACEUTICALS, INC. (US) | 1993-01-07 | — | — | WO | claimed |
| CN-87105736-A | 14, 17 beta-ethano-14 beta-estratrienes and estratetraenes, process for their preparation and pharmaceutical preparations containing them | — | 1988-03-09 | — | — | CN | claimed |